Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Antibiotic Selection00:57

Antibiotic Selection

Overview
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections.

Surgical infections·2021
Same author

Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.

Journal of clinical pharmacology·2019
Same author

Plazomicin: A New Aminoglycoside.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2019
Same author

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.

Surgical infections·2018
Same author

Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis.

Clinical and vaccine immunology : CVI·2016
Same journal

Multiplex mismatch amplification mutation polymerase chain reaction assay for the rapid detection of antimicrobial-resistant determinants in Cutibacterium acnes.

Diagnostic microbiology and infectious disease·2026
Same journal

Tularemia-associated septic shock with pneumonia, lung abscesses, and pleural effusion leading to multiorgan failure: Is Francisella tularensis still a deadly pathogen in the antibiotic era? A case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Impact of Xpert® MRSA/SA blood culture PCR test on antimicrobial utilization at a large teaching hospital.

Diagnostic microbiology and infectious disease·2026
Same journal

Disseminated Mucormycosis and monoclonal gammopathy in a young sarcoidosis patient following COVID-19: A rare case report.

Diagnostic microbiology and infectious disease·2026
Same journal

Human septic arthritis caused by Spiroplasma turonicum.

Diagnostic microbiology and infectious disease·2026
Same journal

Enhanced stability of RPA-CRISPR-Cas12a system for respiratory pathogen detection using Trehalose-Carboxymethyl Chitosan Lyoprotectant.

Diagnostic microbiology and infectious disease·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Tigecycline: an update.

Gary E Stein1, Timothy Babinchak

  • 1Michigan State University, East Lansing, MI 48824, USA. Gary.Stein@hc.msu.edu

Diagnostic Microbiology and Infectious Disease
|January 30, 2013
PubMed
Summary
This summary is machine-generated.

Tigecycline is an effective antibiotic for serious infections, including those caused by resistant bacteria. It offers a favorable safety profile and is comparable to standard treatments for specific infections.

More Related Videos

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
08:51

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling

Published on: June 25, 2015

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

Related Experiment Videos

Last Updated: May 14, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
08:51

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling

Published on: June 25, 2015

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Tigecycline is a broad-spectrum antibiotic effective against challenging pathogens like MRSA and VRE.
  • It exhibits minimal organ toxicity and generally does not require dosage adjustments.
  • Clinical studies demonstrate its efficacy and safety comparable to standard therapies for specific infections.

Purpose of the Study:

  • To provide an updated overview of tigecycline's clinical utility.
  • To review current microbial resistance patterns relevant to tigecycline.
  • To analyze pharmacokinetic/pharmacodynamic data and safety profiles.

Main Methods:

  • Review of clinical studies on tigecycline.
  • Analysis of current antimicrobial resistance data.
  • Examination of pharmacokinetic/pharmacodynamic investigations.
  • Assessment of safety data and analyses.

Main Results:

  • Tigecycline is effective for complicated intra-abdominal infections, skin and skin structure infections, and community-acquired bacterial pneumonia.
  • Its use against multidrug-resistant pathogens in hospital-acquired infections requires ongoing evaluation.
  • Updated data on resistance patterns and PK/PD are presented.

Conclusions:

  • Tigecycline is a valuable option for on-label indications.
  • Further assessment is needed for its role in treating infections with high likelihood of multidrug-resistant pathogens.
  • The drug presents a favorable safety profile with minimal organ toxicity.